CURRENT STRATEGY FOR THE TREATMENT OF RESPIRATORY DISTRESS SYNDROME IN NEWBORNS (literature review)
Abstract
Respiratory distress syndrome (P22.0; ICD-10) is a condition associated with lung immaturity and surfactant deficiency in neonates born prematurely. Treatment of RDS remains a key component of neonatal intensive care. The aim of the study was to analyze current treatment strategies for neonatal respiratory distress syndrome. Materials and methods of the study: scientific literature and methodological recommendations of foreign and domestic authors of recent years were analyzed. Study results: the prognosis for newborns who have received prenatal steroids, respiratory support, and exogenous surfactant therapy is favorable. Mortality is less than 10%, and in some studies, survival rates reach 98% when using advanced treatment methods. The evidence base for the updated recommendations and the emergence of some new positions require the implementation of a national protocol for the management of newborns with RDS, which will improve the quality of medical care for newborns and reduce mortality rates among premature infants and severe complications.
About the Authors
List of references
Alfirevic Z., Stampalija T., Medley N. Cervical stitch (cerclage) for preventing preterm birth in singleton pregnancy // Cochrane Database Syst Rev. 2017; CD008991
American Academy of Pediatrics Steering Committee on Quality Improvement and Management. Classifying recommendations for clinical practice guidelines // Pediatrics. 2004 Sep; 114(3): 874-7.
Bahadue FL, Soll R. Early versus delayed selective surfactant treatment for neonatal respiratory distress syndrome // Cochrane Database Syst Rev. 2012; CD001456
Bamat N., Fierro J., Mukerji A., Wright C.J., Millar D., et al. Nasal continuous positive airway pressure levels for the prevention of morbidity and mortality in preterm infants // Cochrane Database Syst Rev. 2021; 11 (11): CD0127
Committee on Fetus and Newborn; American Academy of Pediatrics. Respiratory support in preterm infants at birth // Pediatrics. 2014 Jan; 133(1): 171-4.
Dargaville P.A., Kamlin CO.F., Orsini F., Wang X., De Paoli A.G., Kanmaz Kutman H.G. Effect of minimally invasive surfactant therapy vs sham treatment on death or bronchopulmonary dysplasia in preterm infants with respiratory distress syndrome: the OPTIMIST-A randomized clinical trial // JAMA. 2021; 2478–87
Davis P.G., Schmidt B.., Roberts R.S., Doyle L.W., Asztalos E, Haslam R. Caffeine for apnea of prematurity trial: benefits may vary in subgroups // J Pediatr. 2010; 382-7
Finer N.N., Carlo W.A., Walsh M.C., Rich W., Gantz M.G., Laptook A.R., Yoder B.A., Faix R.G., Das A., Poole W.K., Donovan E.F., Newman N.S., Ambalavanan N, Frantz ID, Buchter S, Sánchez PJ, Kennedy KA, Laroia N, Poindexter B.B., Cotten C.M., Van Meurs K.P., Duara S., Narendran V., Sood B.G., O'Shea T.M., Bell E.F., Bhandari V., Watterberg K.L., Higgins R.D. Early CPAP versus surfactant in extremely preterm infants // N Engl J Med. 2010 May 27; 362(21): 1970-9.
Ho J.J., Subramaniam P., Davis P.G. Continuous distending pressure for respiratory distress in preterm infants. Cochrane Database Syst Rev. 2015 Jul 04; 2015(7): CD002271
Ho J.J., Subramaniam P., Davis P.G. Continuous positive airway pressure (CPAP) for respiratory distress in preterm infants // Cochrane Database Syst Rev. 2020 Oct15; CD002271
Jobe A.H., Kemp M., Schmidt A., Takahashi T., Newnham J., et al. Antenatal corticosteroids: a reappraisal of the drug formulation and dose //Pediatr Res. 2021; 318–325.
Kapadia V., Oei J.L., Finer N., Rich W., Rabi Y., Wright I.M. Outcomes of delivery room resuscitation of bradycardic preterm infants: a retrospective cohort study of randomised trials of high vs low initial oxygen concentration and an individual patient data analysis // Resuscitation. 2021; 209–217.
Lanciotti L., Correani A., Pasqualini M., Antognoli L., Dell'Orto V.G., Giorgetti C. Respiratory distress syndrome in preterm infants of less than 32 weeks: what difference does giving 100 or 200 mg/kg of exogenous surfactant make // Pediatr Pulmonol. 2022; 2067–73
Lemyre B., Laughon M., Bose C., Davis P.G. Early nasal intermittent positive pressure ventilation (NIPPV) versus early nasal continuous positive airway pressure (NCPAP) for preterm infants //Cochrane Database Syst Rev. 2016; CD005384.
Norman M., Piedvache A., Borch K., Huusom L.D., Bonamy A.E., et al.; Effective Perinatal Intensive Care in Europe (EPICE) Research Group. Association of short antenatal corticosteroid administration-to-birth intervals with survival and morbidity among very preterm infants: results from the EPICE cohort // JAMA Pediatr. 2017; 678–686
Ramaswamy V.V., Abiramalatha T., Bandyopadhyay T., Shaik N.B., Pullattayil S. A..K, Cavallin F. Delivery room CPAP in improving outcomes of preterm neonates in low-and middle-income countries: a systematic review and network meta-analysis // Resuscitation. 2022; 250-63.
Roberts C.T., Owen L.S., Manley B.J., Frоisland D.H., Donath S.M., Dalziel K.M., Pritchard M.A., Cartwright D.W., Collins C.L., Malhotra A., Davis P.G. HIPSTER Trial Investigators. Nasal High-Flow Therapy for Primary Respiratory Support in Preterm Infants // N Engl J Med. 2016 Sep 22; 375(12): 1142-51.
Subramaniam P., Ho J.J., Davis P.G. Prophylactic or very early initiation of continuous positive airway pressure (CPAP) for preterm infants. Cochrane Database Syst Rev. 2021; 10 (10): CD 001243
Schmitz T., Doret-Dion M., Sentilhes L., Parant O., Claris O., Renesme L. Neonatal outcomes for women at risk of preterm delivery given half dose versus full dose of antenatal betamethasone: a randomised, multicentre, double-blind, placebo-controlled, non-inferiority trial // Lancet. 2022; 592–604
Shaffer M.L., Baud O., Lacaze-Masmonteil T., Peltoniemi O.M., Bonsante F., Watterberg K.L. Effect of prophylaxis for early adrenal insufficiency using low-dose hydrocortisone in very preterm infants: an individual patient data meta-analysis // J Pediatr. 2019;136–42.
Singh N., Halliday H.L., Stevens T.P., Suresh G., Soll R., Rojas-Reyes M.X. Comparison of animal-derived surfactants for the prevention and treatment of respiratory distress syndrome in preterm infants // Cochrane Database Syst Rev. 2015 Dec 21; 12: CD010249.
Söderström F., Normann E., Holmström G., Larsson E., Ahlsson F., Sindelar R. Reduced rate of treated retinopathy of prematurity after implementing lower oxygen saturation targets // J Perinatol. 2019; 409–14
Sweet D.G., Carnielli V.P., Greisen G., Hallman M., Klebermass-Schrehof K., et al. European Consensus guidelines on the management of respiratory distress syndrome: 2022 update. Neonatology. 2023;120(1):3–23. DOI: https://doi.org/10.1159/000528914
Tzyy-Rong Huang, Hsiu-Lin Chen, Shu-Ting Yang, Pin-Chun Su, Hao-Wei. The Outcomes of Preterm Infants with Neonatal Respiratory Distress Syndrome Treated by Minimally Invasive Surfactant Therapy and Non-Invasive Ventilation // Chung. Biomedicines. 2024; 838.
Lenyushkina A.A., Andreev A.V., Ionov O.V., Zubkov V.V. Review of recommendations for the care of newborns with respiratory distress syndrome // Neonatology: news, opinions, training. 2024; 12(1): 84-99. DOI: https://doi.org/10.33029/2308-2402-2024-12-1-84-99
National guidelines on neonatology adopted in medical institutions of the healthcare system of the Republic of Uzbekistan. Tashkent. 2017; 237.
How to Cite
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.